Targets › IDH1
15 programs from 14 companies in 66 trials: 27 Phase 2, 24 Phase 1, 14 Phase 3, 1 Phase 4; Oncology, Hematology, Other; next expected readout Nov 2026.
Catalyzes the NADP(+)-dependent oxidative decarboxylation of isocitrate (D-threo-isocitrate) to 2-ketoglutarate (2-oxoglutarate), which is required by other enzymes such as the phytanoyl-CoA dioxygenase. Can also use 2-oxoglutarate as substrate and catalyze the reduction of 2-oxoglutarate to R-2-hydroxyglutarate. (UniProt, O75874)
Open in Phaseline: the race on IDH1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Rigel Pharmaceuticals | Olutasidenib Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1 | Phase 4 | AML (Acute Myeloid Leukemia); High Grade Glioma; Targeted Therapy; Myelodysplastic Syndromes … | Apr 2027 |
| Hutchmed | HMPL-306 IDH1/IDH2 inhibitor | IDH1, IDH2 | Phase 3 | Acute Myeloid Leukemia; Gliomas Harboring IDH1 and/or IDH2 Mutations | Dec 2026 |
| Chia Tai Tianqing Pharmaceutical Group | TQB3454 tablets Selective IDH1 mutant enzyme inhibitor | IDH1 | Phase 3 | Biliary Carcinoma | Dec 2026 |
| Servier Affaires Médicales | Ivosidenib Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1 | Phase 3 | Acute Myeloid Leukemia (AML); Cholangiocarcinoma; Newly Diagnosed Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia … | Oct 2027 |
| Servier Bio-Innovation | Ivosidenib Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1 | Phase 3 | Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen; IDH1-Mutated Malignancies | Feb 2028 |
| Nuvation Bio | Safusidenib Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1 | Phase 3 | Glioma; Grade 2 IDH1-mutant Glioma | Dec 2028 |
| Servier | Vorasidenib (S095032) IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP], mitochondrial inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1, IDH2 | Phase 3 | Residual or Recurrent Grade 2 IDH Mutant Glioma | Oct 2030 |
| Institut de Recherches Internationales Servier (I.R.I.S.) | Vorasidenib IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP], mitochondrial inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1, IDH2 | Phase 2 | Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation; Severe Hepatic Impairment; Grade 2 Glioma; Astrocytoma, IDH-Mutant, Grade 3 … | Nov 2026 |
| Daiichi Sankyo | DS-1001b Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1 | Phase 2 | WHO Grade II Glioma | Feb 2027 |
| Servier | Ivosidenib Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1 | Phase 2 | Cholangiocarcinoma Non-resectable | May 2027 |
| Kissei Pharmaceutical | Olutasidenib Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1 | Phase 2 | Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia | Sep 2030 |
| Eli Lilly | LY3410738 Covalent isocitrate dehydrogenase (IDH) inhibitor | IDH1, IDH2 | Phase 1 | Acute Myeloid Leukemia (AML); Cholangiocarcinoma | May 2027 |
| Katy Peters, MD, PhD | PEPIDH1M vaccine Tumor-specific peptide vaccine targeting IDH1 mutations | IDH1 | Phase 1 | Low Grade Glioma of Brain | Aug 2027 |
| Novartis | IDH305 Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1 | Phase 1 | Advanced Malignancies That Harbor IDHR132 Mutations | Oct 2030 |
| Bristol-Myers Squibb | Ivosidenib (AG-120) Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1 | Phase 1 | Leukemia, Myeloid, Acute | – |
Acute Myeloid Leukemia (12) Acute Myeloid Leukemia (AML) (3) Cholangiocarcinoma (3) Newly Diagnosed Acute Myeloid Leukemia (AML) (2) Myelodysplastic Syndromes (2) AML (Acute Myeloid Leukemia) (2) IDH1 Mutation (2) Acute Myeloid Leukemia With Gene Mutations (2) AML (2) Low Grade Glioma of Brain (2) Glioma (1) Grade 2 IDH1-mutant Glioma (1)
small molecule (14), other (1)
Servier (2) Eli Lilly (1) Nuvation Bio (1) Bristol-Myers Squibb (1) Kissei Pharmaceutical (1) Servier Affaires Médicales (1) Katy Peters, MD, PhD (1) Hutchmed (1) Rigel Pharmaceuticals (1) Servier Bio-Innovation (1) Novartis (1) Daiichi Sankyo (1) Institut de Recherches Internationales Servier (I.R.I.S.) (1) Chia Tai Tianqing Pharmaceutical Group (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.